Francis Lo Sells 51,004 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Francis Lo sold 51,004 shares of the company’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $22.45, for a total transaction of $1,145,039.80. Following the transaction, the insider owned 237,688 shares of the company’s stock, valued at $5,336,095.60. This represents a 17.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Francis Lo also recently made the following trade(s):

• On Thursday, July 2nd, Francis Lo sold 44,838 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $22.59, for a total transaction of $1,012,890.42.
• On Thursday, June 4th, Francis Lo sold 39,741 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $17.49, for a total transaction of $695,070.09.
• On Wednesday, April 8th, Francis Lo sold 22,564 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $15.07, for a total transaction of $340,039.48.

Adaptive Biotechnologies Trading Down 3.2%

Shares of NASDAQ:ADPT opened at $20.82 on Wednesday. The firm’s 50 day moving average is $16.38 and its two-hundred day moving average is $15.94. Adaptive Biotechnologies Corporation has a 52 week low of $9.96 and a 52 week high of $22.80. The firm has a market capitalization of $3.33 billion, a P/E ratio of -63.09 and a beta of 2.07.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.03. The business had revenue of $70.87 million during the quarter, compared to the consensus estimate of $61.03 million. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The business’s revenue was up 35.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.20) earnings per share. Analysts predict that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. JPMorgan Chase & Co. lowered their target price on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. TD Cowen increased their price objective on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Monday, April 20th. Guggenheim boosted their target price on Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Monday, June 29th. Finally, Morgan Stanley cut their target price on Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Adaptive Biotechnologies currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.50.

Institutional Investors Weigh In On Adaptive Biotechnologies

A number of large investors have recently made changes to their positions in ADPT. Perceptive Advisors LLC acquired a new position in Adaptive Biotechnologies in the 1st quarter worth approximately $2,117,000. Bank of America Corp DE lifted its holdings in shares of Adaptive Biotechnologies by 52.3% in the first quarter. Bank of America Corp DE now owns 1,227,917 shares of the company’s stock valued at $17,043,000 after purchasing an additional 421,645 shares in the last quarter. Amundi acquired a new stake in shares of Adaptive Biotechnologies in the first quarter worth $148,000. California State Teachers Retirement System boosted its position in shares of Adaptive Biotechnologies by 28.4% in the first quarter. California State Teachers Retirement System now owns 143,658 shares of the company’s stock worth $1,994,000 after buying an additional 31,782 shares during the period. Finally, SummitTX Capital L.P. purchased a new position in shares of Adaptive Biotechnologies during the first quarter valued at $4,409,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.